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Abstract
A number of risk factors for esophageal and gastric cancers have emerged, yet little is known whether
risk factors map to molecular tumor markers such as overexpression of the tumor suppressor TP53.
Using a US multicenter, population-based case-control study (170 cases of esophageal
adenocarcinomas, 147 gastric cardia adenocarcinomas, 220 non-cardia gastric adenocarcinomas, and
112 esophageal squamous cell carcinomas), we examined whether the risk associated with cigarette
smoking, body mass index (BMI), gastroesophageal reflux disease (GERD), and non-steroidal anti-
inflammatory drug (NSAID) use varied by P53 overexpression. We defined P53 overexpression
through immunohistochemistry of paraffin-embedded tumor tissues, using cutpoints based on
percent of cells positive. Polytomous logistic regression was used to assess differences between each
case group (defined by tumor subtype and P53 expression) and the control group by risk factors. The
proportion of cases overexpressing P53 by tumor subtype was 72% for esophageal adenocarcinoma,
69% for gastric cardia adenocarcinoma, 52% for non-cardia gastric adenocarcinoma, and 67% for
esophageal squamous cell carcinoma. For most tumor subtypes, we found little difference in risk
factors by tumor P53 overexpression. For non-cardia gastric cancer however, an association with
cigarette smoking was suggested for tumors that do not overexpress P53, while larger BMI was
related with tumors that overexpress P53 verses no overexpression. Overall, this study did not find
a clear relationship between P53 protein overexpression and known risk factors for subtypes of
esophageal and gastric cancers. Further research with these tumors is needed to identify molecular
markers associated with variations in the risk factor profiles.
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The P53 protein is a critical regulator of processes important in carcinogenesis, including cell
cycle control, DNA repair, and apoptosis (1). P53 is tightly regulated, normally expressed at
low levels; however, mutation of the gene encoding P53 (TP53) can result in abnormal P53
protein accumulation which has been associated with neoplasia (2). There is evidence that the
nature and distribution of TP53 mutations may reflect exposure to etiologic factors (3,4). For
example, chemical carcinogens in tobacco smoke generally produce transversion mutations,
while endogenous mutagens, such as nitric oxide, cause mostly transition mutations (5).
Furthermore, a strong correlation exists between missense mutations in TP53 and high levels
of protein accumulation (5), so P53 immunohistochemistry has been used as a marker for
mutation. Accordingly, we examined subtypes of esophageal and gastric cancers, to determine
whether P53 overexpression may also vary by risk factors. We have previously shown
differences in non-steroidal anti-inflammatory drug (NSAID) use among individuals with
esophageal and gastric cardia adenocarcinomas that overexpress cyclin D1 when compared to
tumors that do not overexpess this marker (6). P53 overexpression has been described in
subtypes of esophageal and gastric cancers (7–12), but its relation to risk factors is not well-
defined.
A number of risk factors have been identified for esophageal and gastric cancer, with variations
by subtype (i.e. esophageal adenocarcinoma, esophageal squamous carcinoma, gastric cardia
adenocarcinoma, non-cardia adenocarcinomas). Cigarette smoking has been associated with
increased risk, while use of NSAIDs appears to be protective for all four subtypes (13–17). In
contrast, gastroesophageal reflux (GERD), defined in terms of the frequency and severity of
heartburn symptoms, and elevated body mass index (BMI) have been associated with elevated
risk of esophageal adenocarcinoma, while gastric cardia adenocarcinoma has been associated
to a lesser extent only with elevated BMI (18–21). Here we examine the association of these
risk factors with subtypes of esophageal and gastric cancers, stratified by P53 expression status,
in a multicenter study of 649 cases and 695 controls across the United States, to test the
hypothesis that P53 overexpression is the target mechanism by which the known risk factors
smoking, NSAID, GERD, and BMI act in subtypes of esophageal and gastric cancers.
METHODS
Study population
The methods for this population-based case-control study have been reported in detail
elsewhere (14). Briefly, residents newly diagnosed with invasive esophageal or gastric cancers
at ages 30–79 years in Connecticut (from February 1, 1993, to January 31, 1995), New Jersey
(from April 1,1993, to November 30, 1994), and western Washington state (from March 1,
1993, to February 28, 1995) were identified through rapid reporting systems. Population-based
control subjects were selected by random digit dialing (22) for those under 65 years of age and
from the Health Care Financing Administration files for those 65 years of age or older. Cases
and controls were frequency matched to expected age and sex distributions of esophageal and
gastric cardia adenocarcinomas. In New Jersey, cases and controls also were matched on race.
Classification of cases by site of origin and histology was determined by two pathologists
through standardized review of pathology materials and reports from surgery, endoscopy, and
radiology.
Risk factor information
Methods for data collection have been previously described (14,17,20). Briefly, in-person
interviews were conducted with control subjects and cases, as well as next of kin of deceased
cases, for information on demographic characteristics, cigarette smoking and alcohol use, other
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beverage consumption, medical history, use of medications, diet, and occupational history.
Proxy interviews were conducted for 30% of the cases and 3% of controls. For cigarette
smoking, never smoking was defined as having smoked less than 100 cigarettes lifetime or as
having smoked less than one cigarette per day for any 6-month period. A former smoker was
defined as having stopped smoking 2 or more years before the interview (14). NSAID (or
aspirin) users were defined as persons having taken NSAIDs (or aspirin) at least once per week
for 6 months or more (17). To determine the number of episodes of severe heartburn as a
symptom for GERD, subjects were asked “For how many months or years in total did (you/s/
he) have severe heartburn”. The respondents indicated the number of months or years or that
they did not know. In the tables presented, GERD was defined as more than 1 reported GERD
episode per year (20). In addition, we evaluated a more stringent definition of GERD as 13
episodes or more per year, but this did not change interpretation of the findings.
Tumor immunohistochemistry
Archived tumor blocks with adequate tissue for immunohistochemical analyses were acquired
for 649 (56.8%) of the 1130 cancer cases. As reported previously (6), the availability of tumor
tissue varied little by tumor subsite, histology, or stage at diagnosis (data not shown). In
addition, the availability of tumor tissue did not vary by direct versus proxy interview. The
methods for P53 protein analysis have also been described previously (23). In brief, the P53
DO-7 monoclonal antibody (1:50; DAKO Corp., Santa Barbara, CA) was used on dewaxed
formalin-fixed, paraffin sections of tumor, utilizing microwave antigen retrieval (24). The
Immunohistochemical protocol was performed by a Ventana Automated Immunostainer
(Ventana Corp., Tucson, AZ) using a 32-minute incubation of the primary antibody and avidin-
biotin complex immunoperoxidase technique (25). Stains for the slides were performed in
multiple batches in the same lab and a positive and negative control was included to be sure
results were consistent across batches. Nuclear P53 protein staining was assessed by a study
pathologist. The percentage of stained tumor cells was coded as a 5-level ordered categorical
variable where: 0= negative 1= <10%; 2=10–50%; 3=51–90%, and 4=>90% cells stained
positive.
Statistical methods
Odds ratios (OR) and 95% confidence intervals (CI) were estimated for P53+ cases and P53−
cases separately by comparison to controls in unordered polytomous logistic regression models
(26). For the purposes of this study, P53 overexpression was defined as tumors having nuclear
staining in 10% of cells or more, and moderate or strong intensity score of staining. We also
performed sensitivity analyses on the final models using more stringent levels of percent
positive cells. Such models with alternative cutpoints did not change the interpretation of our
findings. For ease of presentation, we refer to these cases with protein overexpression as P53
+ cases throughout the manuscript; those cases with less than 10% positive nuclear staining
are referred to as P53− cases. Five models were evaluated for the following risk factors:
cigarette smoking (never, former, current), BMI (< 25, 25–30, 30+), GERD (No/Yes), any
NSAID use (non-users of any NSAID, any type), and aspirin use (non-users of any NSAID,
aspirin use only). ORs and 95% CIs were computed for P53+ cases relative to P53− cases to
evaluate the significance of the differences in risk by P53 overexpression. The inclusion of the
other risk factors for adjustment (cigarette smoking, BMI, GERD, NSAID use, alcohol
drinking, and education) was also performed in the models. Any variable that changed the
model parameter estimates for P53 overexpression by 10% or more was included in the final
models for each risk factor (26). To account for non-linear relationships with age, age and age
squared (age2) terms were included in the regression models. In addition, models including
and excluding proxy interview status were considered, but they did not appreciably change any
of the results and are not reported here. Lastly, since P53 overexpression has been suggested
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in other tumors to be related to stage, we performed stratified analysis by tumor stage at
diagnosis (local/regional versus distant/advanced stage).
RESULTS
Among cases with tumor slides for immunohistochemistry staining, 64% were found to
overexpress P53, with slight variations by tumor subtype: 72% for esophageal adenocarcinoma,
69% for gastric cardia adenocarcinoma, 52% for non-cardia gastric adenocarcinoma, and 67%
for esophageal squamous cell carcinoma (Table 1). Within tumor subtypes, P53 overexpression
did not vary consistently by study center, age, race, or sex. P53 overexpression (P53+) was
more frequent with advanced stage at diagnosis for esophageal and gastric cardia
adenocarcinomas, although the differences did not reach statistical significance (Table 1).
The associations with cigarette smoking for P53+ and P53− tumors were similar for esophageal
and gastric cardia adenocarcinomas (Table 2). Cigarette smoking was also associated with
elevated risks of both non-cardia gastric adenocarcinoma and esophageal squamous cell
carcinoma regardless of P53 status. However, the risks were generally greater among P53−
tumors (e.g., in non-cardia gastric cancer, OR for P53+ versus P53− case/case differences =
0.49, 95% CI = 0.25–0.96 and OR = 0.62, 95% CI = 0.29–1.35 for former smokers and current
smokers, respectively, relative to never smokers). A high excess risk for all four subtypes was
observed among former and current smokers, but current smokers tended to have higher risks
for all four cancer types.
As expected, excess BMI was significantly associated with increased risks of esophageal
adenocarcinoma and to a lesser extent, gastric cardia adenocarcinoma (Table 3). The elevated
risks did not vary significantly by P53 overexpression, although adenocarcinomas regardless
of subsite, generally had higher risks among P53+ cases than P53− cases when compared with
controls. For example, for non-cardia gastric cancer, the OR comparing P53+ to P53− cases
was 1.16 (95% CI= 0.64–2.10) for those with BMI 25–30 and 2.5 (95% CI=0.98–6.40) for
those with BMI >30. Risks for esophageal squamous cell carcinoma tended to decrease with
increasing BMI, and with no significant differences between P53+ and P53− cases.
A self-reported history of GERD was associated with an elevated risk only for esophageal
adenocarcinomas, with the risk estimates similar for P53+ and P53− tumors (Table 4). The risk
for gastric cardia adenocarcinoma appeared to be inversely associated with GERD, but only
among P53+ cases. GERD was not associated with risk for non-cardia gastric adenocarcinoma,
but was inversely related to esophageal squamous cell carcinoma, regardless of P53
overexpression. Furthermore, a more stringent definition of GERD (13 episodes/year) did not
alter the conclusions (data not shown).
In our study, use of NSAIDs was associated with a reduced risk for all subtypes of esophageal
and gastric cancers as previously reported (6). The inverse associations were comparable for
P53+ and P53− tumors except for gastric cardia adenocarcinomas which showed an inverse
association for P53+ cases and a positive association for P53− cases (Table 5). However, none
of the associations reached statistical significance.
Supplemental analyses using more stringent cutpoints for P53 positivity (50% positive cells)
did not materially alter the findings. Stratification by tumor stage at diagnosis (localized/
regional and distant/metastatic) also did not reveal any consistent differences in risk patterns
by P53 overexpression.
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The present study examined the risk factors associated with subtypes of esophageal and gastric
cancers that were characterized by P53 overexpression status. The preponderance of P53
overexpression in all subtypes of esophageal and gastric cancers in our study is consistent with
previous reports (7–12). However, we did not observe consistent differences in risk patterns
by P53 overexpression status for tumor subtypes.
Cigarette smoking is a well-documented risk factor for esophageal and gastric cancers,
although the magnitude of association varies for tumor subtypes (14,27). In our study, smoking-
related risk for esophageal and gastric cardia adenocarcinomas did not vary by P53
overexpression status, but the risk for non-cardia gastric adenocarcinoma and esophageal
squamous cell carcinoma tended to be higher among P53− than P53+ tumors. Esophageal
squamous cell carcinomas among smokers have been reported with excess transversion
TP53 mutations, which is consistent with the mutation signature of tobacco carcinogens, such
as polycyclic aromatic hydrocarbons and nitrosamines (28,29). Our failure to observe a greater
smoking-related risk for P53+ cases may be due to unstable risk estimates since only 11%
(12/112) of esophageal squamous cell carcinomas reported never smoking and only one P53
− tumor was a never smoker. In contrast, the TP53 mutation signatures in esophageal and
gastric adenocarcinomas feature transition mutations at CpG sites, which is consistent with the
role of endogenous mutagens, such as oxyradicals and nitrogen oxyradicals, rather than
exogenous carcinogens as found in cigarette smoke (4). This is consistent with the similar
smoking-related risks we observed for P53+ and P53− cases of esophageal and gastric
adenocarcinomas, and with the hypothesis that risk factors other than smoking induce P53
inactivation (4,29).
Elevated BMI has been associated with excess risk of esophageal adenocarcinoma, and to a
lesser extent with gastric cardia adenocarcinoma (18,19,21). In our analysis, BMI-related risks
did not vary consistently or significantly by P53 overexpression, although the increases in risk
of adenocarcinomas tended to be more pronounced for P53+ tumors than P53− tumors. While
the mechanism linking obesity to esophageal adenocarcinomas is unclear, a recent study of
Barrett’s esophagus, a precursor state, revealed loss of the chromosomal region (17p) where
TP53 resides among individuals with increased waist-to-hip ratio, another proxy for obesity
besides BMI (30). In addition, mutation of TP53 has been related to dietary factors, including
high intake of fat, protein, or nitrites in gastric cancers (31), suggesting that differences in BMI-
related risk by P53 expression status may be in part a function of nutrient intake.
GERD has been associated with increased risk for esophageal adenocarcinomas (21), and may
act through a chronic inflammatory process that increases the likelihood of TP53 mutation in
esophageal tissue (32). However, the association with GERD in our study did not vary
significantly by P53 overexpression, perhaps because not all TP53 mutations result in P53
overexpression (8), or because P53 is not central to the multi-stage progression from GERD
to adenocarcinoma.
The inverse associations with NSAID use for the tumor subtypes in our study did not vary
consistently by P53 expression. In a recent cross-sectional study of 429 persons with Barrett’s
esophagus, the odds ratio for current regular NSAID users compared with neverusers was 0.3
(95% CI, 0.1–0.7) among individuals with loss of heterozygosity in chromosome 17p (30),
suggesting that NSAID may suppress inactivation of the TP53 locus. Given the lack of an
association between NSAID use and P53 overexpression of the tumor subtypes in our study,
other molecular mechanisms such as cyclin D overexpression(6) may be the pathway by which
this protective factor acts.
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This study took advantage of previous work demonstrating that mutations of TP53 often result
in overexpression of P53 (2,33). However, there are limitations to using protein expression as
a marker for TP53 mutation, since it has been shown that 30–35% of tumors harboring TP53
mutations do not result in protein accumulation (34). Since the prevalence of P53
overexpression increases with advancing tumor stage at diagnosis, survival bias may occur if
any of the risk factors are related also to survival (35). Our results were adjusted for proxy
interviews, conducted primarily for deceased patients or those too ill to be interviewed.
Furthermore, stratification by tumor stage at diagnosis yielded comparable results, arguing
against a systematic bias due to survival.
In summary, this population-based study examined the association of risk factors for subtypes
of esophageal and gastric cancers by P53 overexpression. There was no clear evidence of case
heterogeneity by P53 overexpression except for suggestive differences in the risk association
of non-cardia gastric adenocarcinoma in relation to cigarette smoking and BMI. Given the
differences in risk factors by morphologic subtypes of esophageal and gastric cancer, further
studies with sufficient power to also include molecular subtypes should provide some insights
into causal pathways as targets for prevention.
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